Sonoma BioTherapeutics
1 Letterman Dr
San Francisco
CA
94129
United States
9 articles with Sonoma BioTherapeutics
-
Sonoma Biotherapeutics Appoints Heidi Hagen, MBA as Chief Technical Officer
11/16/2021
Sonoma Biotherapeutics, an immune tolerance company focused on the development of novel regulatory T cell therapies for autoimmune and inflammatory disease, announced the appointment of Heidi Hagen, MBA as Chief Technical Officer.
-
Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary
9/16/2021
Sonoma Biotherapeutics today announced the appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary.
-
Money on the Move: August 4 – 10
8/11/2021
Check out where the money went in the life sciences industry this week. -
Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases
8/4/2021
Sonoma Biotherapeutics’ platform and product candidates aim to restore immune system balance through complementary regulatory T cell (T reg ) therapy and effector T cell (T eff ) conditioning
-
Sonoma BioTherapeutics continues to work toward its goal of restoring immune system balance through complementary regulatory T cell therapy and effector T cell conditioning, this time with the help of an oversubscribed Series B round.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and Degenerative Diseases
9/30/2020
Sonoma Biotherapeutics, a privately held company developing regulatory T-cell therapies for autoimmune and degenerative diseases, announced that it has raised an additional $30 million from investors in its Series A financing, bringing the total to $70 million.
-
Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases
2/6/2020
Company founded by four pioneers of Treg cell biology and cell therapy and financed by a syndicate of leading biotech investors
-
Updated: Parker Institute CEO Jeffrey Bluestone Steps Down to Launch Sonoma Biotherapeutics
2/6/2020
Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, has stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.